Healthcare Industry News:  peripheral artery disease 

Devices Interventional

 News Release - August 28, 2007

FoxHollow Technologies Makes Significant Advancement in the Treatment of Below the Knee Arterial Disease With Introduction of SilverHawk EXL

Equipped with proprietary MEC(TM) Technology, The SilverHawk(R) EXL increases tissue collection capacity and improves ease of use for physicians, representing considerable advancement in Below the Knee treatment of peripheral artery disease

REDWOOD CITY, Calif., Aug. 28 (HSMN NewsFeed) -- FoxHollow Technologies, Inc. (Nasdaq: FOXH ), today announced the launch of its latest advancement in plaque excision technology: the SilverHawk® EXL. This distinct device is part of a broader SilverHawk product family, designed to remove atherosclerotic tissue that blocks arteries in the lower leg of patients suffering from peripheral artery disease (PAD).

The SilverHawk EXL, has a lengthened nosecone and includes MEC(TM) (Micro Efficient Compression) Technology, a novel advancement which features precision laser-drilled vent holes in the tip of the catheter. These micro vent holes release fluid pressure providing more space for the collection of tissue in the tip of the device. When combined with the longer nosecone, this new technology allows for increased tissue collection capacity. These improvements may shorten overall procedure time by reducing the number of insertions required by the physician to remove the diseased tissue. In vitro bench test results demonstrate nearly five times more tissue capture per insertion than the previous device.

"The EXL provides patients with the opportunity to be treated quickly, efficiently and in more areas below the knee," said John Simpson, Ph.D., M.D., FoxHollow's founder and Chief Executive Officer. "With MEC(TM) Technology, a lengthened nosecone and tissue packing capability, the EXL is expected to be a workhorse for below the knee procedures. We are thrilled to be able to provide this technology to physicians in their quest for a better patient experience," he added.

PAD is a condition that afflicts as many as 12 million Americans, and occurs when plaque accumulates in the arteries and blocks blood flow in the legs. These blockages can result in severe leg pain, very limited physical mobility, and ultimately, can lead to amputation. The SilverHawk Plaque Excision System is a minimally invasive method of removing the obstructive plaque and restoring blood flow to the legs and feet. The SilverHawk catheters utilize a tiny rotating blade to shave plaque from artery walls and a reservoir nosecone to collect the excised plaque from the patient. Unlike angioplasty or stenting, SilverHawk plaque excision does not simply push the plaque against artery walls, but instead removes it from the artery.

About FoxHollow Technologies, Inc.

FoxHollow Technologies, Inc. develops and markets endovascular therapeutic devices for the treatment of peripheral artery disease (PAD). PAD results from plaque that accumulates in the arteries and blocks blood flow in the legs. These blockages can result in severe pain for patients and very limited physical mobility. The company's SilverHawk® Plaque Excision System is a minimally invasive method of removing obstructive plaque and restoring blood flow to the legs and feet. FoxHollow also markets the Rinspirator® System for removing thrombus, or blood clots, from occluded arteries in patients suffering from PAD or coronary artery disease (CAD). For more information, please visit our website at

Forward-looking statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this press release regarding FoxHollow's business that are not historical facts may be "forward-looking statements" that involve risks and uncertainties. Specifically, the company's statements regarding certain design improvements to the SilverHawk Plaque Excision System are forward-looking statements involving risks and uncertainties. Forward-looking statements are based on management's current, preliminary expectations, and are subject to risks and uncertainties that could cause actual results to differ from the results predicted and which are included under the caption, "Risk Factors," in our most recent quarterly report on Form 10-Q for the quarter ended June 30, 2007. This quarterly report was filed with the SEC on August 9, 2007, and is available on our investor relations website at and on the SEC's website at Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. FoxHollow undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.

Source: FoxHollow Technologies

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.